Related Experiment Videos
A new approach to dose reduction in chronic schizophrenia
J Hirschowitz1, R Hitzemann, G Burr
1Psychiatry Service, VAMC, Northport, New York.
Summary
The bromocriptine growth hormone test (BGHT) monitors D2 receptor activity in schizophrenia patients on haloperidol. Lowering haloperidol doses revealed symptom changes, suggesting a "just blockade" dose may optimize therapeutic effects.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- D2 receptor activity is crucial in schizophrenia treatment.
- Haloperidol is a common antipsychotic targeting D2 receptors.
- Monitoring receptor activity aids in optimizing antipsychotic dosage.
Purpose of the Study:
- To investigate D2 receptor activity using the bromocriptine growth hormone test (BGHT) during haloperidol dose reduction in chronic schizophrenic patients.
- To determine the relationship between D2 receptor blockade, haloperidol dosage, and psychotic symptom changes.
Main Methods:
- 16 chronic schizophrenic patients on ≥20 mg/day haloperidol underwent BGHT at various haloperidol dose reductions.
- BGHT involved oral bromocriptine (50 µg/kg) to assess growth hormone (GH) response, indicating D2 receptor blockade.
- Plasma haloperidol levels were measured concurrently.
Main Results:
- At baseline (≥20 mg/day haloperidol), bromocriptine-induced GH rise was blocked in all patients.
- D2 receptor blockade escape occurred at lower haloperidol doses (10 mg/day, 5 mg/day, 2.5 mg/day, 0 mg/day).
- Escape from blockade correlated with both decreased positive psychotic symptoms in some and increased symptoms in others, with dose adjustments impacting symptom severity.
Conclusions:
- The BGHT is a valuable tool for guiding haloperidol dose reduction in chronic schizophrenia.
- A "just blockade" dose of haloperidol may represent the minimum effective dose for maximizing therapeutic benefits.
- Individualized D2 receptor monitoring can personalize antipsychotic treatment strategies.